Incyte’s science-first approach and heritage in immunology has formed the foundation of our company. Today, we are building on this legacy as we discover and develop innovative inflammation and autoimmunity treatments to bring solutions to patients in need.
Our research and development efforts in inflammation and autoimmunity are anchored in our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition in chronic immune-mediated dermatologic conditions, including atopic dermatitis, vitiligo, hidradenitis suppurativa and prurigo nodularis.
Research has shown that the JAK-STAT pathway mediates the cellular effects of cytokines involved in the pathogenesis of many immune-mediated dermatologic conditions.
We strive to develop and deliver oral and topical solutions to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis.
Resources
FOR HEALTHCARE PROFESSIONALS

Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please contact our medical team at eumedinfo@incyte.com or visit incyteglobalmedicalinformation.com.
To report a possible Adverse Event (AE) or Product Complaint related to an Incyte product, contact Incyte Global Medical Information. Alternatively, you can report AEs by email: eumedinfo@incyte.com.